Efficacy of recombinant human thrombopoietin in patients with acute-on-chronic liver failure and thrombocytopenia: A prospective, open-label study

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 31, Issue 14

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

HTML

Figures (1-4)

Tables (1-4)

Sum=159

Publishing Process of This Article

Item

Count

Browse

Download

Sum=9

Apr 14, 2025 (publication date) through Apr 15, 2025

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Clinical Trials Study

World J Gastroenterol. Apr 14, 2025; 31(14): 105004
Published online Apr 14, 2025. doi: 10.3748/wjg.v31.i14.105004

Table 4 The adverse reactions, bleeding events and prognosis, n (%)

rhTPO: Recombinant human thrombopoietin.

Citation: Liu G, Tang F, Wang T, Yan JQ, Li FH, Ha FS, Zhang X, Jing L, Liang J. Efficacy of recombinant human thrombopoietin in patients with acute-on-chronic liver failure and thrombocytopenia: A prospective, open-label study. World J Gastroenterol 2025; 31(14): 105004
URL: https://www.wjgnet.com/1007-9327/full/v31/i14/105004.htm
DOI: https://dx.doi.org/10.3748/wjg.v31.i14.105004